These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33647822)

  • 1. Real life experience with mTOR-inhibitors after lung transplantation.
    Bos S; De Sadeleer LJ; Yserbyt J; Dupont LJ; Godinas L; Verleden GM; Ceulemans LJ; Vanaudenaerde BM; Vos R
    Int Immunopharmacol; 2021 May; 94():107501. PubMed ID: 33647822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
    Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis.
    Tejedor-Tejada J; Alonso-Martín C; Almohalla-Álvarez C; Valenzuela EF; Muñoz RN; Delgado LS; Martín CM; Sánchez-Martín F; García-Pajares F; Sánchez-Antolín G
    Transplant Proc; 2020 Jun; 52(5):1507-1510. PubMed ID: 32213292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR inhibitors in pediatric liver transplant recipients.
    Dumortier J; Couchonnal E; Lacaille F; Rivet C; Debray D; Boillot O; Lachaux A; Ackermann O; Gonzales E; Wildhaber BE; Jacquemin E; McLin V
    Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):403-409. PubMed ID: 30528864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
    Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
    Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zeng J; Zhong Q; Feng X; Li L; Feng S; Fan Y; Song T; Huang Z; Wang X; Lin T
    Front Immunol; 2021; 12():663602. PubMed ID: 34539621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of mTORI usage and outcomes in kidney transplant recipients.
    Lim LM; Kung LF; Kuo MC; Huang AM; Kuo HT
    Int J Med Sci; 2021; 18(5):1179-1184. PubMed ID: 33526978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM; Kushwaha SS
    Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
    Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
    Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
    Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
    Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.
    Asante-Korang A; Carapellucci J; Krasnopero D; Doyle A; Brown B; Amankwah E
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28708333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
    Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
    Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion From Calcineurin Inhibitors to Mammalian Target-of-Rapamycin Inhibitors in Heart Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials.
    Qiu Y; Wang X; Fan J; Rao Z; Lu Y; Lin T
    Transplant Proc; 2015 Dec; 47(10):2952-6. PubMed ID: 26707320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
    Hoerning A; Wilde B; Wang J; Tebbe B; Jing L; Wang X; Jian F; Zhu J; Dolff S; Kribben A; Hoyer PF; Witzke O
    Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.
    Lim WH; Eris J; Kanellis J; Pussell B; Wiid Z; Witcombe D; Russ GR
    Am J Transplant; 2014 Sep; 14(9):2106-19. PubMed ID: 25088685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
    Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
    Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation.
    de Paula MI; Medina Pestana JO; Nicolau Ferreira A; Pontello Cristelli M; Fabiano Franco M; Aguiar WF; Tedesco-Silva H; Rosso Felipe C
    Ther Drug Monit; 2016 Feb; 38(1):22-31. PubMed ID: 26121616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.